The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
about
Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.Preclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure.A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer.
P2860
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
@ast
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
@en
type
label
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
@ast
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
@en
prefLabel
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
@ast
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
@en
P1433
P1476
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
@en
P2093
Tate Thigpen
P304
P356
10.1053/J.SEMINONCOL.2006.03.015
P433
P577
2006-04-01T00:00:00Z